In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price ...

Alexander Hardy; President, Chief Executive Officer, Director; Biomarin Pharmaceutical Inc Brian Mueller; Chief Financial Officer, Executive Vice President; Biomarin Pharmaceutical Inc Cristin ...

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know. BioMarin Pharmaceutical beat analysts’ revenue expectations by ...

BioMarin is amassing a portfolio of genetic-disease therapeutics, making historical comparisons with Genzyme (acquired by Sanofi) difficult to avoid. Commercialization and research and development ...